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Abstract
Background: IntralipidH administration at reperfusion elicits protection against myocardial ischemia-reperfusion injury.
However, the underlying mechanisms are not fully understood.
Methods: Sprague-Dawley rat hearts were exposed to 15 min of ischemia and 30 min of reperfusion in the absence or
presence of IntralipidH 1% administered at the onset of reperfusion. In separate experiments, the reactive oxygen species
(ROS) scavenger N-(2-mercaptopropionyl)-glycine was added either alone or with IntralipidH. Left ventricular work and
activation of Akt, STAT3, and ERK1/2 were used to evaluate cardioprotection. ROS production was assessed by measuring
the loss of aconitase activity and the release of hydrogen peroxide using Amplex Red. Electron transport chain complex
activities and proton leak were measured by high-resolution respirometry in permeabilized cardiac fibers. Titration
experiments using the fatty acid intermediates of IntralipidH palmitoyl-, oleoyl- and linoleoylcarnitine served to determine
concentration-dependent inhibition of complex IV activity and mitochondrial ROS release.
Results: IntralipidH enhanced postischemic recovery and activated Akt and Erk1/2, effects that were abolished by the ROS
scavenger N-(2-mercaptopropionyl)glycine. Palmitoylcarnitine and linoleoylcarnitine, but not oleoylcarnitine concentration-
dependently inhibited complex IV. Only palmitoylcarnitine reached high tissue concentrations during early reperfusion and
generated significant ROS by complex IV inhibition. Palmitoylcarnitine (1 mM), administered at reperfusion, also fully
mimicked IntralipidH-mediated protection in an N-(2-mercaptopropionyl)-glycine -dependent manner.
Conclusions: Our data describe a new mechanism of postconditioning cardioprotection by the clinically available fat
emulsion, IntralipidH. Protection is elicited by the fatty acid intermediate palmitoylcarnitine, and involves inhibition of
complex IV, an increase in ROS production and activation of the RISK pathway.
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Introduction
IntralipidH is the brand name of the first safe fat emulsion for
human use, which was invented by the Swedish medical doctor
Arvid Wretlind and approved for clinical use in 1962. Beside
phospholipids (1.2%) and glycerol (2.2%), it consists of a mixture
of neutral triglycerides. The major fatty acid constituents are
linoleic acid (C18:2, ,60%), oleic acid (C18:1, ,30%) and
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palmitic acid (C16:0,,10–15%). In the clinical setting, IntralipidH
is mainly used for parenteral nutrition and serves as solvent of
many lipophilic drugs, which would otherwise be insoluble in
aqueous solutions and could not be injected intravenously [1]. As
rescue therapy, IntralipidH was also found to accelerate detoxifi-
cation of overdosed lipophilic drugs such as local anesthetics, drugs
targeting the central nervous system and various Ca2+ channel
blockers by acting as a ‘‘lipid sink’’ [2]. More recently, Rahman
and colleagues [3] reported marked protection of the heart against
ischemia-reperfusion injury with a 70% reduction in infarct size
when IntralipidH was added at high doses (1% in the isolated heart
or 5 mL/kg body weight in vivo) at the onset of reperfusion. That
study and a follow-up study [4] from the same group observed
activation of protection signaling (Akt, ERK1/2) and phosphor-
ylation (and inhibition) of GSK3b with subsequent increased Ca2+
retention capacity of mitochondria, suggesting inhibition of the
permeability transition pore. However, the fundamental mecha-
nisms causing this marked protection of the heart remain unclear
to date.
Increasing fatty acid oxidation under ischemia/reperfusion
conditions is usually regarded as detrimental, while increasing
glucose oxidation and concomitantly reducing fatty acid oxidation
(Randle cycle) is considered beneficial [5,6,7]. In contrast to this
‘‘iconic principle’’ in cardioprotection by metabolic interventions,
we have recently reported that infarct-remodeled hearts with
limited oxidative capacity accelerate fatty acid oxidation for ATP
production and not glucose oxidation after conditioning against
ischemia/reperfusion injury [8]. Other studies also support the
importance of fat oxidation under conditions of ischemia/
reperfusion [9,10,11] and raise the possibility that by increasing
energy supply, administration of IntralipidH at the onset of
reperfusion could help secure energy production and enhance
postischemic recovery. Consistent with this concept is the notion
that increased fatty acid oxidation plays a beneficial role in the
recovery of IntralipidH-rescued hearts exposed to lethal doses of
local anesthetics [12]. While such an energy boost from fatty acid
oxidation may foster postischemic recovery, mechanisms previ-
ously reported for many types of postconditioning should also be
considered in IntralipidH-mediated cardioprotection. Therefore,
we hypothesized that the formation of reactive oxygen species
(ROS) due to inhibition of the electron transport chain would
activate reperfusion injury salvage kinases (RISK) or signal
transducer and activator of transcription 3 (STAT3) [13,14]. This
hypothesis has not been tested so far and the precise mechanisms
of IntralipidH-induced protection remain elusive. Hence we set out
to investigate the activities of the respiratory complexes as possible
targets of IntralipidH, and further explored the role of ROS. Based
on the concept of a ‘‘gradual wake-up’’ [13], we specifically
hypothesized that IntralipidH would inhibit electron flux and thus
generate ROS at the onset of reperfusion.
Our study now demonstrates that cardioprotection by Intrali-
pidH, observed as improved postischemic LV mechanical function,
is caused by increased ROS production during early reperfusion
and is accompanied by an accumulation of acylcarnitines. The
palmitic acid constituent of IntralipidH initiates postconditioning
by inhibition of the respiratory complex IV, generation of ROS
and activation of RISK. Our data provide a novel metabolic
foundation of IntralipidH-mediated cardioprotection.
Materials and Methods
All materials were from Sigma-Aldrich (St. Louis, MO, USA)
unless otherwise stated. cis-9-octadecenoyl-L-carnitine (oleoylcar-
nitine, C18:1, cisD-9) and cis,cis-9,12-octadecadienoyl-L-carnitine
(linoleoylcarnitine C18:2, cis,cisD-9,12) were not commercially
available and synthesized separately as detailed below.
Synthesis of cis-9-octadecenoyl-L-carnitine
(Oleoylcarnitine, C18:1, cis-9)
Cis-9-octadecenoyl chloride was first prepared by reacting
1.05 mM cis-9-octadecenoic acid (from Sigma Aldrich- St. Louis,
MO) with 2.1 mM thionyl chloride in 30 ml hexane, and the
reaction mixture was heated to 60–80uC in a hot oil bath for 2.5
hours, while stirring, under nitrogen gas flow. The cis-9-
octadecenoyl chloride was distilled to remove all low boiling point
components, hexane and the excess thionyl chloride. Second, the
perchlorate salt of the L-carnitine was prepared by reacting
0.20 mM L-carnitine in 25 ml acetonitrile with 0.24 mM silver
perchlorate and the reaction mixture was stirred for one hour at
room temperature, and the supernatant was collected by
decanting. The cis-9-octadecenoyl chloride from the first step
was added to the supernatant from the second step and the
reaction mixture was stirred at 40uC (hot water bath) for 22 hours.
The reaction mixture was centrifuge at 2,000 rpm for 10 min at
4uC, and the supernatant was collected and the pH was adjusted
to 4 by the addition of sodium bicarbonate. The supernatant was
centrifuged at 2,000 rpm for 10 min at 4uC, to remove the sodium
bicarbonate. The supernatant was again collected by decanting,
and the acetonitrile was evaporated using nitrogen gas till dryness.
The cis-9-octadecenoylcarnitine product was collected, washed
four times using ether 25 ml each time, and the ether was
evaporated and the product was collected, with a 88.26% yield of
cis-9-octadecenoylcarnitine as oily solid component.
Synthesis of cis, cis-9, 12-octadecadienoyl-L-carnitine
(Linoleoylcarnitine, C18:2, cis, cis-9, 12)
Linoleoyl chloride (cis, cis-9, 12-octadecadienoyl chloride) was
first prepared by reacting 1.8 mM cis, cis-9, 12-octadecadienoic
acid in 25 ml hexane with 5.0 mM thionyl chloride and the
reaction mixture was heated to 60–75uC in a hot oil bath for 2.5
hours, while stirring, under nitrogen gas flow. The cis, cis-9,12-
octadecadienoyl chloride was distilled to remove all low boiling
point components, hexane and the excess thionyl chloride.
Second, the perchlorate salt of the L-carnitine was prepared by
reacting 2.5 mM L-carnitine in 35 ml acetonitrile with 3.0 mM
silver perchlorate and the reaction mixture was stirred for one
hour at room temperature, and the supernatant was collected by
decanting. The cis, cis-9,12-octadecadienoyl chloride from step I
was added to the supernatant from the second step and the
reaction mixture was stirred at room temperature for 60 hours.
The reaction mixture was centrifuge at 2,000 rpm for 10 min at
4uC, and the supernatant was collected and the pH was adjusted
to 4.5 by the addition of sodium bicarbonate. The supernatant was
centrifuged at 2,000 rpm for 10 min at 4uC, to remove the sodium
bicarbonate. The supernatant was again collected by decanting,
and the acetonitrile was evaporated using nitrogen gas till dryness.
The product of cis,cis-9,12-octadecadienoylcarnitine (linoleoylcar-
nitine) was collected, washed five times using ether 20 ml each
time, and the ether was evaporated and the product was collected,
with a 82.17% yield of cis,cis-9,12 octadecadienoylcarnitine as oily
component.
Animal Ethics Statement
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication, 8th Edition, 2011) and was approved by
the University of Alberta Animal Policy and Welfare Committee.
Mechanisms of IntralipidH Cardioprotection
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e87205
Working Rat Heart Perfusion Protocols
Male Sprague-Dawley rats (350–400 g) were anesthetized with
pentobarbital (150 mg/kg, intraperitoneally). Each heart was
rapidly removed and perfused initially in a non-working
Langendorff mode with Krebs-Henseleit solution for 15 min.
The working mode perfusion was subsequently established
(11.5 mmHg preload, 80 mmHg afterload, 5 Hz) with a recircu-
lating perfusate of 100 mL (37uC, pH 7.4) gassed with 95% O2/
5% CO2 mixture that consisted of a modified Krebs-Henseleit
solution containing (mmol/L): KCl (4.7), NaCl (118), KH2PO4
(1.2), MgSO4 (1.2), CaCl2 (2.5), NaHCO3 (25), glucose (11),
palmitate (1.2, pre-bound to 3% bovine serum albumin) and
insulin 100 mU/L [8]. All hearts were subjected to 15 min of
37uC zero-flow ischemia and 30 min of reperfusion. Longer
periods of global ischemia would have resulted in no functional
recovery at reperfusion, which would have markedly biased all
metabolic measurements and measurements of metabolic flux
rates. Cardiac output (mL/min) and aortic flow (mL/min) were
measured using ultrasonic flow probes (Transonic T206, Tran-
sonic Systems Inc., Ithaca, NY) placed in the left atrial inflow and
the aortic outflow lines. Left ventricular work (mL/min?mmHg)
was calculated as LVW=cardiac output N (aortic systolic pressure
2 preload). Measurements of mechanical function were averaged
for the pre- and postischemic periods. Hearts were assigned to the
following four groups 1) IR=untreated without IntralipidH
(Baxter, Mississauga, ON) 2) IR/IL= IntralipidH 1% administered
immediately at the onset of reperfusion 3) IR/IL+MPG= Intra-
lipidH 1% plus 10 mM N-(2-mercaptopropionyl)-glycine concom-
itantly administered at the onset of reperfusion, 4) IR/
MPG=10 mM N-(2-mercaptopropionyl)-glycine alone. 1 mM
palmitoylcarnitine (IR/C16:0c), linoleoylcarnitine (IR/C18:2c)
or oleoylcarnitine (IR/C18:1c) were added to the perfusate at
the onset of reperfusion in separate experiments to mimic
IntralipidH protection. In a separate set of experiments with
IntralipidH, reperfusion time was reduced to 3 minutes. Finally,
additional groups of hearts were perfused aerobically (time-
matched, 30 min) in the absence or presence of IntralipidH 1%
to explore the direct effects of IntralipidH on mitochondrial
respiration and oxidative metabolism in absence of ischemic
injury. Cardiac fibers were collected from the apex of the left
ventricle at the end of the perfusions. All hearts were immediately
frozen in liquid nitrogen with Wollenberger clamps and stored at
280uC for subsequent molecular analyses. Additional hearts were
flushed of blood and used to collect fibers to measure complex IV
inhibition, mitochondrial H2O2 release and uncoupling in
response to acylcarnitines in vitro.
High-resolution Respirometry in Permeabilized Cardiac
Fibers
Respiration measurements were performed in saponin-permea-
bilized fibers [8] prepared from freshly excised left ventricular
apex of either perfused or unperfused hearts using the Oroboros
Oxygraph 2 K system (Oroboros, Innsbruck, Austria). Measure-
ments were conducted in an assay solution containing 110 mM
sucrose, 60 mM K-lactobionate, 20 mM taurine, 0.5 mM EGTA,
3 mM MgCl2?6 H2O, 10 mM KH2PO4, 20 mM HEPES, and
1 g/l BSA (pH 7.1 at 30uC). Characterization of the mitochon-
drial respiratory complexes was obtained using the following
substrates in the presence of 5 mM ADP or absence of ADP (leak
respiration): pyruvate (5 mM)/malate (2 mM), succinate (10 mM),
ascorbate (2 mM)/tetramethylphenylenediamine dihydrochloride
(TMPD; 0.5 mM), and palmitoylcarnitine (20 mM)/malate
(2 mM). Substrates used together with the inhibition of complex
I by rotenone (0.5 mM), complex III by antimycin A (2.5 mM), and
complex IV by azide (100 mM) provided complex-specific flux
measurements. Proton leak in permeabilized cardiac fibers was
measured as detailed in the supplementary file Protocol S1.
Citrate Synthase Activity
The activity of the mitochondrial matrix marker enzyme citrate
synthase (CS) was measured at 412 nm by monitoring the
formation of thionitrobenzoate, as previously described [15].
Mitochondrial Complex III Activity
The assay was performed using MitoTox OXPHOS complex
III activity kit (MitoSciences, Eugene, OR). Mitochondrial protein
was isolated from tissue homogenates. After centrifugation at
10,000 g for 15 min 4uC, the resulting pellet was resuspended for
protein concentration determination. 2–3 mg of mitochondrial
protein was used in a 96-well plate for complex III activity
measurement by monitoring the conversion of oxidized cyto-
chrome c to its reduced form, as indicated by the linear increase in
the absorbance at 550 nm.
Amplex Red Assay for the Determination of
Mitochondrial Hydrogen Peroxide (H2O2) Release in
Permeabilized Cardiac Fibers
To assess mitochondrial H2O2 emission capacity from collected
cardiac fibers, we determined H2O2 production under non-
respiring conditions and under active oxidative phosphorylation
(5 mM ADP) using a combination of pyruvate (5 mM)/malate
(2 mM) and succinate (10 mM) as substrates to ensure full
operation of the citric acid cycle, as well as to provide both
NADH and FADH2 to feed electrons through complexes I and II
of the mitochondrial electron transport chain, respectively. H2O2
production was measured fluoroscopically using Amplex Red
(Invitrogen, Carlsbad, CA) [16]. Horseradish peroxidase (HRP;
2 U/ml) catalyzed the reaction between Amplex Red (20 mM) and
H2O2 in the presence of exogenously added superoxide dismutase
(10 U/ml), forming the fluorophore resorufin, which was moni-
tored at excitation/emission wavelengths of 540/590 nm (Synergy
H4 hybrid multi-mode microplate reader, BioTek Instruments,
Inc. Winooski, VT USA). H2O2 standard curves were generated
for each independent experiment, to calculate the cumulative
mitochondrial H2O2 production from the resorufin signal. H2O2
production at each time point was then determined by calculating
the rate of change in H2O2 concentration over 20 min.
Background rates of fluorescence change in the absence of added
substrates were subtracted for each experiment. At the end of each
experiment, cardiac fibers were collected and homogenized for
citrate synthase (CS) activity assay. H2O2 production rate was
expressed as pmol/min/IU CS activity.
Aconitase Assay for the Determination of ROS Production
in Mitochondrial Matrix of Perfused Hearts
Aconitase activity was measured according to the protocols of
Gardner et al. [17] from mitochondria isolated from perfused
hearts. Mitochondria were isolated in the presence of 5 mM
sodium citrate to protect aconitase from oxidation. Mitochondrial
preparations were diluted to 0.1 mg/ml in 50 mM Tris-HCl,
pH 7.4 containing 0.05% Triton X-100. Aconitase activity was
assayed as the rate of NADP+ reduction (molar extinction
coefficient for NADPH at 340 nm is 6,220 M21cm21) at 37uC
in a reaction mixture containing 50 mM Tris-Cl (pH 7.4), 5 mM
sodium citrate, 0.6 mM MnCl2, 0.2 mM NADP
+, 1 U/ml
isocitrate dehydrogenase, and 0.1 mg/ml mitochondrial protein.
Mechanisms of IntralipidH Cardioprotection
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One unit of aconitase converted 1.0 nmol of citrate to isocitrate
per minute at 37uC.
Immunoblotting for Akt, STAT3, and ERK1/2 and Enzyme-
linked Immuno-absorbent Assay for Akt Activity
Frozen heart tissue was homogenized in ice-cold buffer
containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet
P-40, supplemented with protease and phosphatase inhibitor
cocktail mix (Sigma-Aldrich). The homogenate was centrifuged at
1000 g for 10 min at 4uC. The resulting supernatant was collected
for protein concentration determination (Bradford assay) and used
for immunoblotting in sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). The primary antibodies for Akt,
STAT3 and ERK1/2 were rabbit anti-Akt, rabbit anti-STAT3
and rabbit anti-ERK1/2 (all 1:500) and rabbit anti-pAkt, rabbit
anti-pSTAT3 and rabbit anti-pERK1/2 (all 1:500) (Cell Signaling
Technology, Danvers, MA). Tubulin (mouse monoclonal, Sigma-
Aldrich, T6074) was used as loading control. Immunoreactivity
was visualized by horseradish peroxidase-conjugated antibodies
using a peroxidase-based chemiluminescence detection kit (ECL)
(PerkinElmer, Woodbridge, Ontario, Canada). The intensity of
the bands was quantified using ImageJ** software. The total Akt
activity was determined from cytosolic fractions based on solid
phase enzyme-linked immuno-absorbent assay from Enzo (Enzo
Life Sciences, Farmingdale, NY). Frozen heart tissue was
homogenized in buffer containing 10 mM Hepes (pH 7.4),
1.5 mM MgCl2, 10 mM KCl, 0.3 M sucrose, 0.05% Nonidet P-
40, and 5 mM 1,4-dithiothreitol supplemented with protease and
phosphatase inhibitor cocktail mix. After centrifugation at
10,000 g for 15 min 4uC, the resulting supernatant was subjected
to protein concentration determination (Bradford assay). The color
reaction was measured in a microplate reader at 450 nm.
Mass Spectrometry for Acylcarnitine Profiling
Tissue levels of acylcarnitine species were measured using
electrospray ionization tandem mass spectrometry [7]. Acylcarni-
Figure 1. Functional recovery in IntralipidH-treated (Panel A) and acylcarnitine-treated hearts (Panel B) subjected to 15 min of
ischemia and 30 min of reperfusion. LVW, left ventricular work. Basal, average LVW before ischemia. Rep, average LVW during postischemic
reperfusion. IR, untreated hearts exposed to 15 min of ischemia and 30 min of reperfusion (IR). IR/IL, hearts exposed to IR and 1% IntralipidH at the
onset of reperfusion. IR/C16:0c, IR/C18:1c, and IR/C18:2c, hearts exposed to IR and 1 mM palmitoyl-, oleoyl-, or linoleoylcarnitine at the onset of
reperfusion. MPG, N-(2-mercaptopropionyl) glycine (10 mM) added at the onset of reperfusion. *, significantly different from all other groups. N= 6–7
hearts in each group.
doi:10.1371/journal.pone.0087205.g001
Mechanisms of IntralipidH Cardioprotection
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tines were extracted from heart tissue with methanol and
quantified using eight isotopically labeled internal standards
(Cambridge Isotopes Laboratories, Andover, MA). Precursor ions
of m/z 85 in the mass range of m/z 150 to 450 were acquired on a
PE SCIEX API 365 LC-ESI-MS/MS instrument (AppliedBiosys-
tems, Foster City, CA).
Oxidative Metabolism: Contribution of IntralipidH to Fatty
Acid Substrate Metabolism in Perfused Hearts
In separate experiments, competition for b-oxidation between
albumin-bound radiolabeled palmitate and fatty acid constituents
released from IntralipidH was determined in aerobically perfused
hearts [18] to estimate IntralipidH’s contribution to substrate
metabolism and to further evaluate a possible effect on glucose-fatty
acid oxidation partitioning (Randle cycle) [19]. Glucose and fatty acid
oxidation were determined by perfusing the hearts with [U-14C]glu-
cose and [9,10-3H]palmitate, respectively. Total myocardial 14CO2
production and 3H2O production were determined every 10 min.
Rates expressed as mmol/g dry wt/min were calculated for each time
interval and were averaged for 30 min of perfusion.
Statistical Analysis
Values are given as mean (SEM) or median (25th, 75th
percentile) depending on the underlying data distribution for the
indicated number of independent observations (n). The signifi-
cance of differences in hemodynamic and metabolic variables
among groups was determined by Student t-test (two groups) or by
analysis-of-variance (ANOVA) followed by the Student-Newman-
Keuls method for posthoc analysis or by non-parametric methods
(Mann-Whitney rank sum test or Kruskal-Wallis test) depending
on the underlying data distribution. Differences are considered
significant if p,0.05. The inhibitory effect of palmitoylcarnitine
and linoleoylcarnitine on respiratory chain complex IV activity
was measured by nonlinear curve fitting of a 4-parameter logistic
function to the experimental data as follows:
relative inhibition~ minz
(max{min)
1z(
x
IC50
)Hillslope
IC50, is the half maximal inhibitory concentration, Hillslope is
the slope of the concentration-response curve, max and min are
extreme values (no inhibition and maximum inhibition, respec-
tively). SigmaPlot Version 12 (Systat Software, Inc., San Jose, CA
95110 USA) was used for all analyses.
Results
Cardioprotection by IntralipidH Administered at the
Onset of Reperfusion is ROS-dependent and is Mimicked
by Palmitoylcarnitine
Hearts treated with IntralipidH (1% administered at the onset
of reperfusion) showed marked recovery (79%62% of baseline)
Figure 2. Early activation of Akt and ERK1/2 by ROS in IntralipidH-treated hearts. Panel A: p-Akt to total Akt immunoblots from tissue
samples collected 3 min after reperfusion. Panel B: p-STAT3 to total STAT3 immunoblots from same tissue samples. Panel C: Akt activity
measurements. Panel D: p-ERK1/2 to total ERK immunoblots from same tissues. IR, untreated hearts exposed to 15 min of ischemia and 3 min of
reperfusion (IR). IR/IL, hearts exposed to IR and 1% IntralipidH at the onset of reperfusion. MPG, N-(2-mercaptopropionyl) glycine (10 mM) added at the
onset of reperfusion. Data are mean (SEM). N= 6 hearts in each group.
doi:10.1371/journal.pone.0087205.g002
Mechanisms of IntralipidH Cardioprotection
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compared with untreated hearts (24%61%) (Figure 1A). Ad-
ministration of pamitoylcarnitine (1 mM) at the onset of
reperfusion fully mimicked IntralipidH protection (74%62% of
baseline; Figure 1A). However, administration of linoleoylcarni-
tine (1 mM), oleoylcarnitine (1 mM) or glycerol (0.11 g per
100 mL as in a 1% IntralipidH emulsion) did not result in any
protection (glycerol: 33%69%). The ROS scavenger MPG
abolished both IntralipidH- and pamitoylcarnitine-mediated
cardioprotection (Figure 1).
ROS Released from the Mitochondrial Electron Transport
Chain Trigger Activation of Akt and ERK1/2 during Early
Reperfusion in IntralipidH-treated Hearts
Although previous work identified RISK, i.e. Akt and ERK1/2,
as mediators of IntralipidH-induced cardioprotection [3], the
mechanism of RISK activation remains unclear. We hence tested
whether ROS would be required to activate RISK or STAT3. Rat
hearts were either untreated or were exposed to IntralipidH 1%,
IntralipidH plus MPG or MPG alone at the time of reperfusion.
IntralipidH activated Akt (Figure 2A) but not STAT3 (Figure 2B)
at early reperfusion (3 min). ROS scavenging with MPG
prevented activation of Akt (Figure 2C and 2D) and abolished
protection (Figure 1). Administration of MPG alone did not affect
Akt activation. Likewise, IntralipidH activated ERK1/2, which
was abolished by MPG (Figure 2D). Similar to IntralipidH,
palmitoylcarnitine-induced protection was strongly ROS-depen-
dent, i.e. inhibited by the ROS scavenger MPG (Figure 1). We
then determined H2O2 emission capacity from energized and non-
energized mitochondria of cardiac fibers collected after 3 min of
reperfusion in untreated and IntralipidH-treated hearts using
Amplex Red in the presence of exogenously added Cu/Zn
superoxide dismutase. This assay detects superoxide released from
the entire electron transport chain into the intermembrane space
and the mitochondrial matrix in response to metabolic stimula-
tion. Our experiments showed a marked ROS burst from
mitochondria in hearts treated with IntralipidH at the time of
early reperfusion, concomitant with RISK activation (Figure 3A).
Loss of aconitase activity, a specific and sensitive marker of ROS
production within the mitochondrial matrix, revealed only slightly
lower aconitase activity consistent with some matrix-released ROS
formation at 3 min of reperfusion in IntralipidH-treated hearts
(Figure 3B).
Palmitoylcarnitine Inhibits Mitochondrial Electron
Transport Chain at Complex IV in a Concentration-
dependent Manner and Induces ROS Production
Inhibition of the respiratory chain activity promotes ROS
production from mitochondria and is known to be a common
basic mechanism of cardioprotection [13]. To identify the site of
mitochondrial ROS production in IntralipidH-treated hearts, we
measured mitochondrial enzymes activities (either polarograph-
ically or spectrophotometrically) in permeabilized cardiac fibers
from rat hearts aerobically perfused in the presence and absence
of IntralipidH 1%. IntralipidH did not decrease complex I, II
and III activities, but markedly decreased complex IV activity
(Table 1, Table S1). The fact that complex IV inhibition did
not affect overall oxygen consumption when using complex I
and complex II substrates is well known and represents an
inherent feature of the mitochondrial respiratory chain to
maintain a constant electron flow despite variations in complex
IV activity [20]. To test which of the fatty acid constituents of
IntralipidH would elicit inhibition of complex IV activity, we
used acylcarnitines of palmitic (C16:0c), oleic (C18:1c) and
linoleic acids (C18:2c), the main constituents of IntralipidH and
intermediates of fatty acids, which directly access mitochondria.
These acylcarnitines were titrated to permeabilized cardiac
fibers energized with complex IV substrates to establish the
concentration-dependent inhibition of complex IV. Palmitoyl-
and linoleoylcarnitine induced concentration-dependent inhibi-
tion of complex IV activity (Figure 4A). The IC50 values for
palmitoyl- and linoleoylcarnitine were quite similar (Table 2).
Conversely, oleoylcarnitine inhibited complex IV activity only
modestly at very high concentrations (500 mM) (Figure 4A).
Complex IV inhibition by palmitoylcarnitine (150 mM) increased
H2O2 release from energized cardiac fibers (Figure 4B).
Linoleoylcarnitine (150 mM) also slightly increased H2O2 release,
but this did not reach statistical significance (Figure 4B).
Figure 3. IntralipidH-induced formation of ROS in cardiac fibers
collected 3 min after reperfusion. Panel A: Hydrogen peroxide
(H2O2) emission capacity from mitochondria as determined by Amplex
Red assay. *significantly different from IR. Panel B: Loss of aconitase
activity in IntralipidH-treated hearts (PANOVA = 0.002). IR, untreated
hearts exposed to 15 min of ischemia and 3 min of reperfusion (IR).
IR/IL, hearts exposed to IR and 1% IntralipidH at the onset of
reperfusion. Basal, without substrates. +subst, with added substrates.
AER, hearts with time-matched aerobic perfusion. Data are mean (SEM).
N = 6 hearts in each group.
doi:10.1371/journal.pone.0087205.g003
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IntralipidH and Palmitoylcarnitine Similarly Induce ‘‘Mild
Uncoupling’’
Two mitochondrial carriers – uncoupling proteins (UCP) and
the adenine nucleotide translocase (ANT) – display enhanced
proton conductance when they are activated by ROS or fatty
acids [21,22,23]. We thus tested whether IntralipidH-treated
hearts would also exhibit increased uncoupling. Cardiac fibers
were collected at the end of 30 min reperfusion and UCP- and
ANT-mediated proton leak were measured using the specific
blockers guanosine diphosphate and carboxyatractyloside, re-
spectively. UCP- and ANT-mediated uncoupling was markedly
increased in IntralipidH-treated hearts (Figure 5A). The ROS
scavenger MPG diminished ANT- but not UCP-mediated leak,
suggesting a possible mechanistic role of leak respiration in the
recovery from ischemia-reperfusion injury. Experiments with
cardiac fibers directly exposed to palmitoyl- and linoleoylcarni-
tine confirmed increased uncoupling via UCP by both
acylcarnitines and via ANT by palmitoylcarnitine only
(Figure 5B).
Accumulation of Acylcarnitines in IntralipidH-treated
Hearts without Contribution to Substrate Metabolism
Hearts subjected to ischemia-reperfusion and exposed to
IntralipidH 1% accumulated linoleoyl- and oleoylcarnitine starting
at early reperfusion (Figure 6A), suggesting mitochondrial uptake
of IntralipidH-derived fatty acid constituents. Additional experi-
ments showed that there was no reduced utilization of the
radiolabeled albumin-bound palmitate (1.2 mM) in the presence
of 1% IntralipidH during aerobic perfusion of hearts at a constant
workload [24], implying minimal competition for b-oxidation
between albumin-bound and IntralipidH-derived fatty acids and
thus no relevant contribution of IntralipidH to substrate metab-
olism (Figure 6B). Also, there was no decrease in glucose oxidation
in hearts exposed to 30 min of 1% IntralipidH perfusion in the
presence of 1.2 mM palmitate in the perfusate, i.e. no change in
glucose-fatty acid oxidation partitioning (Randle cycle) (Figure 6B).
Discussion
IntralipidH-mediated postconditioning improves recovery of
postischemic mechanical function, involves activation of RISK
(but not STAT3), and is clearly dependent on ROS formation
during early (3 min) reperfusion. Additional experiments revealed
a novel metabolic foundation underlying IntralipidH-induced
cardioprotection that involves the accumulation of acylcarnitines
in mitochondria, which inhibits electron transport at complex IV,
generates ‘‘protective’’ ROS and thus activates RISK (see
Figure 7). Surprisingly, and in contrast to what one would expect
from the fatty acid composition of IntralipidH, the results of our
study indicate that the unsaturated fatty acids of the emulsion are
not essential to IntralipidH-mediated protection. Rather, cardio-
protection is mediated by palmitoylcarnitine arising from the
release of palmitate from IntralipidH, a fatty acid that only
constitutes ,10–15% of the emulsion. This conclusion is
supported by the following findings. First, administration of
palmitoylcarnitine, but not the C18-carnitines, at the time of
reperfusion fully mimicked IntralipidH-mediated cardioprotection.
Second, fatty acids were released from the emulsion and
metabolized to acylcarnitines that accumulated in cardiac tissue.
Third, palmitoylcarnitine, but not linoleoylcarnitine or oleoylcar-
nitine, stimulated ROS production as a consequence of complex
IV inhibition. Fourth, cardioprotection by IntralipidH or palmi-
toylcarnitine were both MPG-dependent indicating an essential
role of ROS production in their mechanism of action. Collectively,
our data show that inhibition of complex IV during the early
(3 min) reperfusion by palmitoylcarnitine generated from Intrali-
pidH elicits a form of pharmacological postconditioning that
involves ROS generation and activation of RISK, and is a novel
and highly effective mechanism of cardioprotection.
Is Cardioprotection by IntralipidH Linked to Enhanced
Substrate Metabolism?
IntralipidH was first approved clinically for parenteral nutrition
and was later found beneficial during cardiac reperfusion [25]
where it improved contractility of the stunned canine myocardium
when administered 15 min following initiation of reperfusion.
Interestingly, oxfenicine, a carnitine palmitoyl transferase-1
inhibitor, abolished this effect suggesting a mechanism involving
enhanced energy substrate availability or substrate oxidation. A
second study in rabbits [26] confirmed the beneficial effect of
IntralipidH and identified two constituents, linoleic acid and
phospholipids, as the protective agents. While these observations
Table 1. Assessment of mitochondrial respiratory chain function.
Substrate/electron donor Site(s) of electron input Method Results
AER AER/IL p-value
pyruvate/malate Complex I (NADH:ubiquinone oxidoreductase) HRR 8.3 (0.6) 7.0 (0.4) 0.074
pyruvate/malate/succinate Complex I+II HRR 10.7 (0.8) 12.2 (0.8) 0.243
succinate Complex II (succinate:ubiquinone oxidoreductase) HRR 6.1 (0.7) 7.8 (0.5) 0.080
decylubiquinol Complex III (ubiquinol:ferricytochrome c oxidoreductase) SP 8.5 (0.7) 8.1 (0.3) 0.652
ascorbate/TMPD Complex IV (cytochrome c oxidase) HRR 22.2 (1.6) 16.3 (1.5 0.024
palmitoylcarnitine/malate Complex I+Electron transfer flavoprotein-ubiquinone
oxidoreductase
HRR 2.9 (0.3) 2.6 (0.2) 0.434
Rat hearts were aerobically perfused with/without Intralipid (1%). Complex I, complex II, and complex IV function was measured polarographically by monitoring
oxygen consumption in presence of specific substrates and ADP in saponin-skinned cardiac fibers using high-resolution respirometry (HRR). Complex III enzymatic
activity was assayed spectrophotometrically (SP). The measured oxygen consumption (normalized to citrate synthase activity) is expressed as nmol O2*s
21/CS. Complex
III activity is expressed as mOD*min21/mg mitochondrial protein. Data are presented as mean (SEM). N = 6–10 in all groups.
Abbreviations:
AER, aerobically perfused hearts without treatment; AER/IL, aerobically perfused hearts exposed to Intralipid (1%); TMPD, tetramethyl-p-phenylene diamine, an artificial
electron carrier which is reduced by ascorbate producing electrons that are transferred to cytochrome c; OD, optical density.
doi:10.1371/journal.pone.0087205.t001
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suggest that provision of additional energy substrates in the form of
fatty acids during reperfusion is the underlying mechanism of
IntralipidH-mediated cardioprotection, more recent reports from
Eghbali’s group indicate activation of Akt/ERK1/2 and inhibition
of GSK3b when IntralipidH is administered right at the onset of
reperfusion, either in a Langendorff mouse heart model (1%
IntralipidH) or in an in vivo rat model (20% IntralipidH, 5 mL/kg
body weight) [3]. These data are consistent with the concept of
postconditioning where RISK are activated during the earliest
stages of reperfusion [27] and also consistent with reports showing
activation of RISK but not STAT3 in pharmacological as opposed
to ischemic postconditioning [28]. Although Eghbali’s group
demonstrated a reduction in mitochondrial Ca2+ overload and the
prevention of the permeability transition pore opening by
IntralipidH [3], both representing downstream events of RISK
activation, the molecular mechanisms of IntralipidH-mediated
Figure 4. Complex IV inhibition by metabolites of IntralipidH fatty acid constituents. Panel A: Concentration-dependent inhibition of
complex IV by palmitoyl(C16:0c)-, oleoyl(C18:1c)-, and linoleoylcarnitine (C18:2c) in permeabilized cardiac fibers. Complex IV inhibition is given as
relative decrease in oxygen consumption. Panel B and C: Concentration-dependent hydrogen peroxide (H2O2) emission capacity determined by
Amplex Red assay in permeabilized cardiac fibers exposed to increasing concentrations of palmitoyl- and linoleoylcarnitine. *, significantly different
from untreated. Data are mean (SEM). N= 6 hearts in each group/concentration.
doi:10.1371/journal.pone.0087205.g004
Table 2. Fitting parameters for the acylcarnitine inhibitor
curves.
compound IC50 [mM] 95% CI [mM] Hillslope 95% CI
Palmitoylcarnitine
(C16:0c)
72.3 (37.7;108) 20.86 (21.07; 20.65)
Linoleoylcarnitine
(C18:2c)
65.6 (49.9;81.4) 21.58 (21.99; 21.16)
Oleoylcarnitine
(C18:1c)
NA NA NA NA
CI, confidence interval; IC50, the inhibitor concentration that reduces the
response by 50%. NA, not applicable.
doi:10.1371/journal.pone.0087205.t002
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protection, specifically the link between IntralipidH as a pharma-
cologically complex fat emulsion with potential impact on
substrate and energy metabolism and the activation of RISK,
and ultimately protection itself remained unresolved.
Our experiments now clearly demonstrate that under aerobic
and constant workload conditions, the rate of exogenous palmitate
oxidation was unaffected by IntralipidH indicating that there was
no significant competition for b-oxidation by fatty acids potentially
released from IntralipidH by endothelium-bound lipoprotein
lipase. Overall fatty acid oxidation was also likely unaffected as
there was no change in glucose-fatty acid oxidation partitioning as
predicted by the Randle Cycle [19]. However, analysis of tissue
acylcarnitine content revealed that triglyceride hydrolysis indeed
occurred as tissue contents of linoleoylcarnitine or oleoylcarnitine
were significantly higher in IntralipidH-treated hearts. Collectively,
these observations question the idea of IntralipidH as a mere
enhancement of energy substrate supply.
Role of ROS Production in IntralipidH-mediated
Cardioprotection
The ability of the ROS scavenger, MPG, to prevent IntralipidH-
mediated cardioprotection strongly suggests participation of ROS.
Indeed, enhanced ROS production due to inhibition of the
respiratory chain either by short episodes of ischemia or by
pharmacological means is a common mechanism of ‘‘condition-
ing’’-mediated cardioprotection [13]. In this concept, ROS
generated from electrons leaking from the respiratory chain of
mitochondria activate RISK and/or Survivor Activating Factor
Enhancing Pathway (SAFE) [27,28] involved in cardioprotection.
We therefore tested whether IntralipidH or its constituents would
indeed inhibit specific complexes of the electron transport chain.
To avoid interference with the ‘‘biochemical threshold effect’’ [29]
inherently functional in respiratory complexes subjected to
metabolic stress of ischemia/reperfusion, we determined the
effects of IntralipidH on individual respiratory complex activities
under aerobic conditions. IntralipidH inhibited exclusively com-
Figure 5. Uncoupling by IntralipidH and acylcarnitines. Panel A: Uncoupling by uncoupling proteins (UCP) and adenine nucleotide translocase
(ANT) were measured in cardiac fibers collected at the end of 30 min reperfusion. N-(2-mercaptopropionyl)-glycine (MPG) inhibits ANT- but not UCP-
mediated uncoupling.#, significantly different from IR and IR/MPG. *, significantly different from all other groups. Panel B: Cardiac fibers respiring on
succinate (leak respiration) were exposed to 150 mM palmitoyl-(C16:0c) and linoleoylcarnitine (C18:2c) and UCP- and ANT-mediated uncoupling were
determined. IR, untreated hearts exposed to 15 min of ischemia and 30 min of reperfusion (IR). IR+IL, hearts exposed to IR and 1% IntralipidH at the
onset of reperfusion. IR/IL+MPG, hearts exposed to IR and 1% IntralipidH +10 mM N-(2-mercaptopropionyl) glycine (MPG) at the onset of reperfusion.
*, significantly different from all other groups. @, significantly different from C18:2c. Data are mean (SEM). N= 6 hearts in each group.
doi:10.1371/journal.pone.0087205.g005
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plex IV [30], a target inhibited by other cardioprotective agents
such as carbon monoxide or hydrogen sulfide [31,32]. The release
of ROS by IntralipidH was confirmed directly as measured by
Amplex Red in the presence of superoxide dismutase. This assay
measures superoxide release toward matrix (complex I) as well as
intermembrane space (complex III), and was more distinct and
robust than when ROS production was determined by the loss of
aconitase activity, which exclusively measures superoxide released
toward matrix. The topology of superoxide release from multiple
sources of the respiratory chain supports the view of a downstream
inhibition of the electron flux by IntralipidH at complex IV [33].
Current literature describes both protective and deleterious
effects of ROS [34,35]. A burst of ROS during reperfusion is
associated with injury, but a controlled amount of ROS during the
preconditioning stimulus or at the onset of reperfusion in a
postconditioning protocol triggers protective signaling and reduces
ischemia-reperfusion injury [28,35,36,37,38,39]. Thus, in the
context of ischemia-reperfusion, the effects of ROS are ‘‘site-’’
and ‘‘time-sensitive’’, i.e. site and time will ultimately determine
whether ROS are beneficial or detrimental. Since administration
of the postconditioning stimulus has to occur at the onset of
reperfusion to be effective and postconditioning protection is
ROS-dependent, the concept emerges that postconditioning by
IntralipidH and possibly other protective agents promotes produc-
tion of small amounts of ROS during early reperfusion, but during
the course of reperfusion significantly reduces ROS formation, an
Figure 6. Accumulation of acylcarnitines and effects on oxidative metabolism in IntralipidH-treated hearts. Panel A: Accumulation of
long-chain acylcarnitines in hearts reperfused for 3 min and 30 min. Panel B: Lack of competition for b-oxidation between exogenous radiolabeled
palmitate and fatty acid constituents released from IntralipidH and no alteration in glucose oxidation (Randle cycle). AER, time-matched aerobically
perfused hearts. AER/IL, time-matched aerobically perfused hearts treated with 1% IntralipidH for 30 min. IR 39 or 309, untreated hearts exposed to
15 min of ischemia and 3 or 30 min of reperfusion, respectively. IR/IL 39 or 309, hearts exposed to 15 min of ischemia and 3 or 30 min of reperfusion
and 1% IntralipidH at the onset of reperfusion. *, significantly different from the corresponding untreated group. Data are mean (SEM). N = 6 hearts in
each group.
doi:10.1371/journal.pone.0087205.g006
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idea, which is further supported by our observation that
IntralipidH-induced ROS production occurred simultaneously
with RISK activation. Since administration of MPG to untreated
hearts did not result in any cardioprotection, we infer that
administration of MPG after successful IntralipidH postcondition-
ing would show the same protection as IntralipidH alone. This has
been indeed shown by Penna et al. using the ROS scavenger N-
acetylcysteine, but ROS were not measured directly in that study
[39].
Interestingly, IntralipidH-induced ROS production was accom-
panied by enhanced UCP- and ANT-mediated leak respiration
[21,23,40]. This uncoupling feedback mechanism relieves pressure
on the electron transport chain when the membrane potential is
high through ‘‘leakiness’’ of the inner mitochondrial membrane
and thus prevents continuing production of high rates of
potentially noxious ROS [40]. On the other hand, mild
uncoupling during reperfusion is beneficial per se and may indeed
represent another mechanism by which IntralipidH and palmi-
toylcarnitine protect the heart against reperfusion injury [41].
Role of Fatty Acids Released from IntralipidH
Only palmitoylcarnitine mimicked the beneficial actions of
IntralipidH while the other two acylcarnitines (i.e., linoleoylcarni-
tine or oleoylcarnitine), had no cardioprotective action. Impor-
tantly, as for IntralipidH-mediated cardioprotection, the beneficial
action of palmitoylcarnitine was also abolished by MPG. Indeed,
an examination of the direct effects of the acylcarnitines revealed
that, although linoleoylcarnitine and palmitoylcarnitine concen-
tration-dependently inhibited complex IV, only palmitoylcarni-
tine-mediated inhibition of complex IV was accompanied by ROS
production. These observations strongly suggest that palmitoyl-
carnitine is the active cardioprotective metabolite of IntralipidH
and is supported by an earlier observation that palmitoylcarnitine
enhances postischemic cardiac function [42]. The inability of the
unsaturated fatty acid intermediates to increase ROS production
as opposed to the saturated palmitoylcarnitine may be explained
by their differential effects on respiratory control [43] and
antioxidant properties [44,45]. We have not determined the
mechanism by which the low concentration of palmitoylcarnitine
(1 mM) is effective despite being administered in the presence of a
high concentration of palmitate (1.2 mM). Possibly, palmitoylcar-
nitine has preferential access to its intramitochondrial target
(complex IV) as it by-passes a number of steps required for the
access of palmitate; these include release from albumin, transport
into the cytoplasm, acylation to palmitoyl CoA prior to conversion
into palmitoylcarnitine.
The increase in mitochondrial H2O2 emission capacity at
palmitoylcarnitine concentrations of ,150 mM suggests accumu-
lation in a microcompartment. In fact, the accumulation of
substrate intermediates in microenvironments (microcompartmen-
tation) is a common feature in mitochondria [46,47], and the
existence of multiple substrate pools within mitochondria is
thought to be advantageous in metabolic regulation and efficiency
[47]. Since b-oxidation is dysfunctional and inhibited by high
levels of NADH, FADH2 and acetyl-CoA during early reperfusion,
accumulation of acyl-CoAs and more so long-chain acylcarnitines
is substantial under these conditions [24,48]. We speculate that
administration of additional acylcarnitines during early reperfu-
sion may lead to an initial peak of long-chain acyl-CoAs, which are
known to decelerate carnitine/acylcarnitine translocase and
carnitine palmitoyl transferase-2 via product feedback inhibition.
This would further increase accumulation of acylcarnitines in the
intermembrane space in close proximity to complex IV. Unfor-
tunately, relevant changes in metabolite concentrations, in our
case of palmitoylcarnitine, occurring exclusively in a microcom-
partment such as the intermembrane space and/or the inner
mitochondrial membrane in a short time window are very
challenging to measure and may go undetected. Irrespectively,
Tominaga and colleagues [49] reported that palmitoylcarnitine as
low as 1 mM administered to permeabilized ventricular rat
myocytes hyperpolarized the mitochondrial membrane and
induced ROS production, which is in accordance with inhibition
of the electron flux in mitochondria. Like our own study, that
study used permeabilized myocytes, which provide the unique
Figure 7. Proposed mechanism of IntralipidH-induced cardioprotection. Metabolites of fatty acid constituents released from IntralipidH
accumulate in the intermembrane space (IMS) in early reperfusion when b-oxidation is still dysfunctional. An initial peak of acyl-CoAs in the
mitochondrial matrix may also inhibit carnitine/acylcarnitine translocase (CACT) and carnitine palmitoyl transferase II (CPT II) via product feedback
inhibition, which would further boost acylcarnitine accumulation in the intermembrane space. Acylcarnitines, namely palmitoylcarnitine, inhibit
complex IV of the respiratory chain (causing superoxide release at complex I (toward matrix) and at complex III (toward IMS). ACS, acyl-CoA synthase
cyt c, cytochrome c. CPT I, carnitine palmitoyl transferase I. FFA, free fatty acids. IMM, inner mitochondrial membrane. LC, long-chain. OMM, outer
mitochondrial membrane. Q, Q-junction is the point in the respiratory chain where electron flow from complex I and from complex II converge.
doi:10.1371/journal.pone.0087205.g007
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opportunity to examine mitochondria under more physiological
conditions, namely the control of cytosolic acylcarnitine concen-
trations without changing extramitochondrial Ca2+, ATP or other
substrates.
The mechanism(s) by which acylcarnitines, and more specifi-
cally palmitoylcarnitine, inhibit complex IV remain unclear.
Complex IV is a dimeric enzyme of 13 subunits per monomer,
which is regulated by availability of substrates, interference with
the catalytic cycle, multiple allosteric regulations and covalent
posttranslational modifications [30,50], and organized with other
respiratory complexes (namely I and III) in functional super-
complexes (‘‘respirasomes’’) [51]. Direct interaction of amphipha-
tic substances such as palmitoylcarnitine with complex IV was
recently reported [52], and as the Hillslope of palmitoylcarnitine-
mediated inhibition is not significantly different from 21, the
existence of a specific binding site and a bimolecular interaction
may be postulated. Clearly, additional molecular studies will be
required to unravel the details of palmitoylcarnitine-mediated
inhibition of complex IV.
Limitations
Our model assessed cardioprotection as improved recovery of
post-ischemic mechanical function. Although this reflects a model
of reversible injury (stunning), it has significant advantages,
specifically in view of the metabolism-targeted questions which
we wanted to address. Any longer periods of global ischemia
would have resulted in no functional recovery at reperfusion,
which would have markedly biased all metabolic measurements.
Although only palmitoylcarnitine mimics IntralipidH-mediated
cardioprotection in a ROS-dependent manner, it was unexpected
that increases in palmitoylcarnitine tissue levels were not
detectable in IntralipidH-perfused hearts. Nevertheless, C18:2-
carnitine accumulated in IntralipidH-treated hearts during early
reperfusion, and C18:2-carnitine and C18:1-carnitine were each
increased by 5 nmol/g wet wt at the end of reperfusion. Clearly,
such increases in C18:2-carnitine and C18:1-carnitine indicate
that fatty acids were released from IntralipidH, but as palmitic acid
is a low abundance constituent (10–15%) of IntralipidH and as
palmitoylcarnitine is likely to accumulate in microcompartments
in mitochondria, a difference in total tissue concentrations may not
be detectable.
We cannot completely rule out that other constituents of the
relatively poorly-defined fat emulsion may also contribute, at least
in part, to the observed beneficial effects of IntralipidH. However,
in additional experiments we excluded the possibility that glycerol,
which is also part of the emulsion (0.11 g per 100 mL in a 1%
IntralipidH emulsion), exerts protective effects in the heart.
Summary
In conclusion, our data describe a new mechanism of
postconditioning cardioprotection elicited by the fatty acid
intermediate palmitoylcarnitine, and further provide a novel
metabolic foundation for cardioprotection by the clinically
available fat emulsion, IntralipidH, that involves inhibition of
complex IV, an increase in ROS production and activation of the
RISK pathway.
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